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Abstract
The present study evaluated the effects of various dosages of soybean isoflavone extract on lipid profiles, lipid peroxidation and antioxidant activities
in streptozotocin-induced diabetic rats. The one normal control group was fed an AIN-76-based experimental diet and four diabetic groups were
fed the same diet, supplemented with four different levels of soybean isoflavone extract for seven weeks. The daily dosages of pure isoflavone 
for four diabetic groups were set to be 0 mg (diabetic control), 0.5 mg (ISO-I), 3.0 mg (ISO-II) and 30.0 mg (ISO-III) per kilogram of body
weight, respectively. The plasma total cholesterol levels and the TBA-reactive substances contents in the liver and kidney were significantly lowered
in ISO-II and ISO-III groups compared to those in the diabetic control group. The levels of plasma HDL-cholesterol, plasma vitamin A and hepatic
superoxide dismutase were significantly increased in those two groups compared with the diabetic control group. The present study demonstrated
the possibility that the diets supplemented with 3.0 mg and 30.0 mg of soybean isoflavone extract may have beneficial effects on the plasma lipids, 
tissue lipid peroxidation and partly on antioxidant system in diabetic animals and there were no significant differences between the ISO-II and 
ISO-III groups. The results suggest that the effective daily dosage level of isoflavone for improving lipid metabolism in diabetic rats may be above
3.0 mg per kilogram body weight.
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Introduction5)
Isoflavones, one of the phytoestrogens have structural and 
functional similarity to human estrogen with affinity to the 
estrogen receptor (Kudou et al., 1991). They contain three main 
compounds, in four chemical forms; aglycones (daidzein, genistein 
and glycitein), glucosides (daidzin, genistin and glycitin), their 
malonyl-glycoside and acetyl-glycoside forms (Ohta et al., 1980). 
Recent epidemiological evidences and experimental data from 
animal studies strongly support the beneficial effects of isoflavones 
in preventing various chronic diseases (Anderson et al., 1999; 
Setchell & Cassidy, 1999). The most abundant food sources of 
isoflavones are soybeans and their products (Wang & Murphy, 
1994). Soybeans contain 12 types of isoflavones (Anderson et 
al., 1998; Kuiper et al., 1997) and the contents of soy isoflavones 
can vary from 50 to 300 mg/100 g (Eldridge & Kwolek, 1983). 
Soy isoflavones have been reported to attenuate bone loss from 
the lumbar spine in perimenopausal women (Alekel et al., 2000), 
to lower blood cholesterol levels (Jenkins et al., 2002; Kirk et 
al., 1998; Raines & Ross, 1995), and to have antioxidant 
properties  in vivo and in vitro experiments (Wei et al., 1993; 
Wei et al., 1996). Due to these abilities of soybean isoflavones, 
they have shown the beneficial effects on prevention and 
attenuation in chronic diseases including cancers (Zhang et al., 
2004), cardiovascular diseases (Teede, 2001), osteoporosis (Arjmandi 
et al., 1996) and menopausal symptoms (Somekawa et al., 2001).
Recently, it has been reported that soy isoflavones may also 
have favorable effects on diabetes mellitus in animals and 
humans. Genistein was reported to increase glucose-stimulated 
insulin secretion in both insulin-secreting cell lines and mouse 
pancreatic islets (Liu et al., 2006) and effectively prevent the 
glucose autoxidation mediated LDL oxidation which results in 
atherosclerosis (Exner et al., 2001). Jayagopal et al. (2002) 
demonstrated that supplementation with phytoestrogens had the 
beneficial effects on insulin resistance, glycemic control and lipid 
profiles in postmenopausal women with type 2 diabetes. Ali et 
al. (2005) showed that isoflavones had hypoglycemic and 
hypolipidemic effects in lean SHR/N-cp rats but not in obese 
rats. Lee (2002) exhibited that soybean isoflavone extract had 
positive effects on the elevation of plasma vitamin A and vitamin 
E in diabetic animals.
However, to our knowledge, the studies investigating the effects 
of soybean isoflavone supplementation on lipid metabolism 
associated with diabetes mellitus are in short. Also, recently, 
inconsistent results have been reported for the effects of 
isoflavones in diabetic rats. Lee (2006) investigated the effects 
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Table 1. The composition of the experimental diets 
Ingredients
Experimental groups
Control ISO-I ISO-Ⅱ ISO-Ⅲ
g/100 g diet
   Cornstarch 15.00 15.00 15.00 15.00
   Sucrose 50.00 50.00 50.00 50.00
   Casein 20.00 20.00 20.00 20.00
   Corn oil  5.00 5.00 5.00 5.00
   Cellulose  5.00 5.00 5.00 5.00
AIN-76 Vitamin mix
1)   1.00 1.00 1.00 1.00
AIN-76 Mineral mix
2)  3.50 3.50 3.50 3.50
Cholinechloride  0.20 0.20 0.20 0.20
DL-methionine  0.30 0.30 0.30 0.30
mg/100 g diet
Isovone 40
3) 0.00 1.03 6.20 62.00
total pure isoflavone 0.00 0.42 2.53 25.35
1) AIN-76 vitamin mix (g/kg mix) : thiamin HCl 0.6, riboflavin 0.6, pyridoxine HCl 0.7, 
nicotinic acid 3, D-calcium pantothenate 1.6, folic acid 0.2, cyanocobalamin 0.001, 
retinyl  palmitate  0.8  (500,000  IU/g),  DL-α-tocopherol  acetate  20  (2501  IU/g), 
cholecalciferol  0.0025,  menaquinone  0.005,  sucrose  to  make  1  kg 
2) AIN-76 mineral mix (g/kg mix) : calcium phosphate dibasic 500, sodium chloride 
74, potassium citrate monohydrate 220, potassium sulfate 52, magnesiumoxide 
24,  manganous  carbohydrate  3.5,  ferric  citrate  6,  zinc  carbonate  1.6,  cupric 
carbonate 0.3, potassium iodate 0.01, sodium selenite 0.01, chromium potassium 
sulfate  0.55,  sucrose  to  make  1  kg 
3) Isovone 40 (Product No. HF-2002-038, Bioland Inc. Seoul, Korea) contains 40.9% 
of total pure isoflavone which consists of 36.9% total aglycone type (22% daidzein, 
11.7%  glycitein,  6.39%  genistein)  and  4%  total  glycoside  type 
of genistein (60 mg/100 g diet) and soy protein (20 g/100 g 
diet)-supplemented diets administered to streptozotocin-induced 
diabetic rats for three weeks and reported the beneficial effects 
on the levels of lipids in the serum and liver as well as the 
activities of antioxidant enzymes in the liver. On the other hand, 
Hsu et al. (2003) found no favorable effect on the plasma lipid 
levels and the antioxidant enzyme activities in diabetic rats fed 
a diet supplemented with isoflavones (240-1920 mg/100 g diet) for 
24 days. Additionally, we judged that the dosages of isoflavones 
administered to diabetic rats in these studies were enormously 
high. Kim and Kwon (2001) reported that total isoflavone intake 
per capita in Korean population was estimated as 14.88 ± 6.26 
mg/d (genistein : 7.32 ± 3.24 mg/d , daidzein 5.81 ± 2.88 mg/d, 
and glycitein 1.75 ± 0.52 mg/d) and Lee et al. (2000) presented 
that the mean intake of Korean middle-aged women was assessed 
to be 24.11 mg/d (0.0 mg-144.30 mg). We already reported that 
2.5 mg/100 g diet of soybean isoflavone had the beneficial effects 
on glucose tolerance and suppression of weight loss in streptozotocin- 
induced diabetic rats (Shim et al., 2007). 
Therefore, the purpose of this study was to examine the effects 
of supplementation of soybean isoflavone on the lipid profiles 
as well as the antioxidant activities in streptozotocin-induced 
diabetic rats at the lower dosage than those used in the previous 
studies (Hsu et al., 2003; Lee, 2006). Additionally, we investigated 
the adequate level of supplementation of soybean isoflavone 
extract which may exhibit the beneficial effects on the lipid 
profiles and antioxidant system in diabetic animal. 
Materials and Methods 
Experimental animals and diet 
We used the same experimental animals and diets as described 
in our previous paper (Shim et al., 2007). Briefly, eighty 
weanling male Sprague-Dawley rats (Biogenomics Co., Korea) 
were divided into five groups; normal control group, diabetic 
control group, and three diabetic experimental groups supplemented 
with three different levels of isoflavone; ISO-I (0.5 mg/kg 
BW/day; 0.4 mg/100 g diet), ISO-II (3.0 mg/kg BW/day; 2.5 
mg/100 g diet) and ISO-III (30.0 mg/kg BW/day; 25.4 mg/100 
g diet). The amounts of isoflavone were calculated based on 
approximate average daily feed intake (30 g) of mature rats and  
the initial mean body weight (257 g) of experimental rats. All 
diets contained an identical concentration of energy and nutrients 
(Table 1) and the animals were fed experimental diets for seven 
weeks. 
Induction of diabetes 
The method of diabetes induction was described in our 
previous paper (Shim et al., 2007). Briefly, diabetes was induced 
by an injection of streptozotocin (Sigma Chemical, St Louis, MO, 
USA) at a dose of 50 mg/kg BW. The rats were considered to 
be diabetic only if their fasting blood glucose levels exceeded 
180 mg/dL. The maintenance of the diabetic state was confirmed 
by measuring the fasting blood glucose level at the 5
th week 
of the experimental period. 
Blood and tissue preparation
The blood and tissue preparations were described in our 
previous paper (Shim et al., 2007). Briefly, after fasting for 12 
hours, the blood was drawn from the inferior vena cava of the 
rats with a syringe treated with heparin (100 units/mL). The 
plasma was separated by centrifuging at 3,000 rpm for 20 minutes 
and stored frozen at -70℃. The liver, kidney and heart tissues 
were excised, rinsed, weighed and stored in a liquid nitrogen 
tank. 
Assessment of concentrations of plasma and tissue lipids 
The concentrations of triglyceride (Bucolo & David, 1973), 
total cholesterol (Allain et al., 1974) and HDL-cholesterol 
(Finley  et al., 1978) in the plasma were measured using 
enzymatic analysis kits (Asan pharmaceuticals, Hwasung, 
Korea). Total lipids in liver tissue were extracted by the Folch 
method (Folch et al., 1957), and then triglyceride (Sidney & 
Bernard, 1973) and total cholesterol (Sale et al., 1984) 
concentrations were measured using commercial enzymatic kits 
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Table 2. HPLC conditions for the determination of plasma vitamin A and E 
Conditions
Column μBondapak C18  (30 cm×3.9 mm, 10 μm)
Detector UV 290 nm
Mobile phase Methanol : H2O (95:5)
Flow rate 2.5 mL/min 
Sample injection 25 μL
Attenuation 16
PT value 200
Chart speed 1 ㎝/min
Assessment of lipid peroxides in plasma and urine
We assessed the lipid peroxides as thiobarbituric acid-reactive 
substances (TBARS) by measuring malondialdehyde (MDA) 
levels in the plasma and tissues. TBARS in the plasma and urine 
were measured according to the Taladgis method (Taladgis et 
al., 1964). An aliquot (0.5 mL) of plasma or urine sample was 
mixed with 3 mL of 5% trichloroacetic acid and 1 mL of 0.06 
M TBA, then incubated in 80℃ water bath for 90 minutes. The 
mixtures were cooled to room temperature, centrifuged at 2,000 
rpm for 15 minutes and the absorbance of the supernatants was 
then measured at 535 nm. Nelson et al. (1993)
  have reported 
that TBARS in urine presented in association with the amount 
of creatinine excreted are statistically more significant; we 
presented the data as nmol MDA/µmoles creatinine. Creatinine 
in urine was measured according to the Jaffé reaction method 
(The Korean Society of Food Science and Nutrition, 2000) by 
using a kit (Asan pharmaceuticals). 
Assessment of lipid peroxides in tissues
TBARS in the liver, kidney and heart tissues were measured 
according to the Uchiyama and Mihara method (Uchiyama & 
Mihara, 1978). After mixing 0.5 g of tissue and 9 times volume 
of 0.01 M sodium phosphate buffer (pH 7.0), the mixture (0.5 
mL) was homogenized and added to the solution composed of 
3 mL of 1% phosphoric acid and 1 mL of 0.06 M TBA, and 
then boiled for 45 minutes. After cooling, the mixture was added 
to 4 mL of n-butanol and centrifuged at 3,000 rpm for 10 minutes. 
The supernatant absorbance was measured at 520 and 535 nm, 
and the difference of absorbance was used to calculate the 
peroxide level.
Preparation of hepatic antioxidant enzymes source 
A total of 2 g of liver tissue was homogenized with 5 times 
volume of 0.25 M sucrose solution at 4℃ using a glass teflon 
homogenizer (Glascol, 099C K44, USD). In order to discard cell 
debris, the homogenates were centrifuged at 600 ×g for 10 
minutes. Then, 3 mL of the supernatant was centrifuged at 10,000 
×g for 20 minutes at 4℃ to obtain the mitochondria supernatant 
and then 5 mL of the supernatant was centrifuged at 105,000 
×g for 1 hour at 4℃ using an ultracentrifuge (Beckman, Optima 
TLX-120) to obtain the cytosol supernatant. The protein contents 
in the cytosolic fraction were determined by the Bradford method 
(Bradford, 1976) with bovine serum albumin as the standard. 
Assay of catalase activity
The activity of catalase was measured by the Abei method 
(Abei, 1974). A total of 0.1 mL of 30 mM H2O2 was added 
to 2.89 mL of 50 mM potassium phosphate buffer (KH2PO4: 
NaH2PO4, 1:1.5, pH 7.0). The mixture was incubated for 5 
minutes at 25℃ and then the absorbance was measured at 240 
nm. Then, 10 ㎕ of liver tissue preparations was added to the 
mixture and incubated for 5 minutes at 25℃. The absorbance 
was then measured at 240 nm for 5 minutes. The H2O2 
decomposition rate was calculated and the activity was expressed 
as H2O2  μmol/min/mg protein.
Assay of glutathione peroxidase activity 
Glutathione peroxidase (GPx) was determined by the Paglia 
and Valentine method (Paglia & Valentine, 1967). One tenth mL 
of 30 mM glutathione reductase, 0.1 mL of 6 mM NADPH and 
0.1 mL of 25 µM H2O2  were subsequently added to 2.6 mL 
of 0.1 M Tris-HCl buffer (pH 7.2) and incubated for 5 minutes 
at 25℃. Then, 0.1 mL of liver tissue preparations was added 
to this mixture and incubated at 25℃  for 5 minutes. The 
absorbance was then measured at 340 nm. A molar extinction 
coefficient of 6.22 mM
-1cm
-1 was used and the activity was 
expressed as oxidized NADPH nmol/min/mg protein. 
Assay of superoxide dismutase activity 
Superoxide dismutase (SOD) was assayed by the Marklund 
and Marklund method (Marklund
  &
  Marklund, 1974). SOD was 
detected based on its ability to inhibit the superoxide-mediated 
reduction. One tenth mL of liver tissue preparations and 0.1 mL 
of 15 mM pyrogallol were added to 2.8 mL of 50 mM Tris-HCl 
buffer (pH 8.6) containing 10 mM EDTA. After incubation for 
10 minutes at 25℃, the reaction was terminated by adding 0.1 
mL of 1 N HCl and the absorbance was then measured at 420 
nm. The enzyme unit was defined as the amount inhibiting the 
autoxidation of pyrogallol by 50%. 
Assessment of antioxidant nutrients (vitamin A & E) 
concentration in plasma 
The concentrations of vitamin A and vitamin E in the plasma 
were measured using the Bieri HPLC method (Bieri et al., 1979). 
Table 2 shows the HPLC conditions for the determination of 
vitamin A and E. One hundred ㎕ of α-tocopheryl acetate and 
100  ㎕ of retinyl acetate were added to 200 ㎕ of plasma as 
an internal standard and the solutions were mixed. A total of Jee-youn Shim et al. 221
Table 3. Effects of soybean isoflavones extract supplementation on plasma lipids concentrations and atherogenic index in STZ-induced diabetic rats
Groups (n)
2) TG (mg/dl) TC (mg/dl) HDL-C (mg/dl) HDL-C/TC (%) AI
3)
Normal control (10) 257.23 ± 8.78
A1) 99.98 ± 3.12
A 50.75 ± 3.00
A 51.19 ± 3.27
A 1.12 ± 0.02
B
Diabetic control (8) 221.63 ± 9.75
Bns 86.88 ± 3.23
Ba 32.79 ± 2.37
Ba 36.14 ± 1.42
Ba 1.65 ± 0.03
Cb
Diabetic ISO-Ⅰ (9) 224.78 ± 7.56
B 84.98 ± 1.90
Ba 35.75 ± 3.14
Ba 42.07 ± 2.45
Ba 1.38 ± 0.02
BCb
Diabetic ISO-Ⅱ (13) 231.95 ± 6.21
AB 80.79 ± 1.17
Bb 41.38 ± 2.27
ABb 51.24 ± 1.27
Ab 0.82 ± 0.01
Aa
Diabetic ISO-Ⅲ (12) 243.36 ± 10.10
AB 76.66 ± 2.31
Bb 42.67 ± 2.57
ABb 55.42 ± 1.45
Ab 0.94 ± 0.01
ABa
ISO:  soybean  isoflavone  extract,  STZ:  streptozotocin,  TG:  triglyceride,  TC:  total  cholesterol,  HDL:  high  density  lipoprotein,  C:  cholesterol,  AI=atherogenic  index 
1) Mean ± S.E.
2) Number  of  animals 
3) AI=(TC-HDL-C)/HDL-C
Different  capital  superscripts  in  the  same  column  indicate  significant  difference  (p<0.05)  among  5  groups  by  Duncan's  multiple  comparison  test. 
Different  small  superscripts  in  the  same  column  indicate  significant  difference  (p<0.05)  among  4  diabetic  groups  by  Duncan's  multiple  comparison  test. 
ns  N o t  s ig n if i c a n t l y  d i f f e r e n t  a m o n g  4  d i a b e t i c  g r o u p s  ( p <0.05)
Table 4. Effects of soybean isoflavone extract supplementation on hepatic lipid
concentrations in STZ-induced diabetic rats 
Groups (n)
2) Triglyceride Total cholesterol
(mg/g tissue)
Normal control (10) 35.61 ± 3.04
A1) 19.69 ± 0.53
NS
Diabetic control (8) 26.34 ± 1.15
Bns 21.26 ± 0.71
ns
Diabetic ISO-Ⅰ (9) 27.96 ± 2.89
B 22.77 ± 0.89
Diabetic ISO-Ⅱ (13) 24.85 ± 2.24
B 22.78 ± 0.83
Diabetic ISO-Ⅲ (12) 25.72 ± 1.41
B 23.32 ± 0.53
ISO  :  soybean  isoflavone  extract,  STZ  :  streptozotocin 
1) Mean ± S.E.
2) Number  of  animals 
Different  capital  superscripts  in  the  same  column  indicate  significant  difference 
(p<0.05)  among  5  groups  by  Duncan's  multiple  comparison  test. 
Different  small  superscripts  in  the  same  column  indicate  significant  difference 
(p<0.05)  among  4  diabetic  groups  by  Duncan's  multiple  comparison  test. 
NS N o t  s i g n i f ic a n t ly  d if f e r e n t  a m o n g  5  g r o u p s  ( p <0.05)
ns Not  significantly  different  among  4  diabetic  groups  (p<0.05) 
200 ㎕ of heptane for HPLC analysis was added to the solution 
and the mixture was centrifuged at 1500 rpm for 5 minutes. The 
supernatant was then collected in a brown vial of interception 
light. This supernatant was filtered using a 0.45 µM membrane 
filter (Millipore Corporation, Bedford, MA 01730) and dried 
under N2 gas. This extract was dissolved in a diethyl ether: 
methanol (1:3, v/v) solution and was then analyzed by HPLC 
(Waters 500). 
Statistical analysis 
Data were presented as means and standard errors of the mean. 
Group means were compared by an Analysis of Variance using 
Duncan’s multiple range test and differences were considered 
to be statistically significant at p value of less than 0.05. All 
statistical tests were performed by using the Windows SPSS 
program (SPSS, Chicago, IL, USA: Version 10.0).
Results
Effect on plasma and hepatic lipids
The plasma triglyceride and total cholesterol levels in the 
diabetic control group were significantly lower (p<0.05) than 
those in the normal control group (Table 3). Among diabetic 
rats, there were no significant differences (p<0.05) in the 
triglyceride levels. However, the levels of plasma total cholesterol 
in ISO-II and ISO-III groups were significantly lower (p<0.05) 
than those in the diabetic control and ISO-I groups. The 
HDL-cholesterol level and the ratio of HDL-cholesterol/total 
cholesterol in the diabetic control group were significantly lower 
(p<0.05) than those in the normal control group. Among diabetic 
groups, the ISO-II and ISO-III groups showed significantly 
higher (p<0.05) HDL-cholesterol levels and ratios of HDL- 
cholesterol/total cholesterol than diabetic control and ISO-I 
groups. The atherogenic index (AI) of the diabetic control group 
was significantly higher (p<0.05) than that of the normal control 
group. Among the diabetic groups, the ISO-II and ISO-III groups 
exhibited significantly lower (p<0.05) AI than the diabetic control 
and ISO-I groups.
The hepatic triglyceride level in the diabetic control group was 
significantly lower (p<0.05) than that in the normal control group 
and there were no significant differences among the diabetic 
groups (Table 4). There were no significant differences (p<0.05) 
in the level of hepatic total cholesterol among all groups 
including the normal control, diabetic control and three 
isoflavone-supplemented groups. 
Effect on the lipid peroxides levels in plasma, urine and tissues 
We expressed the lipid peroxides as TBARS by measuring the 
MDA levels in plasma, urine and tissues. MDA is the final 
product of the degradation of lipid peroxides, which has been 
used as a biochemical index of lipid peroxide-mediated tissue 
damages in vivo (Pierro
  et al., 1992). The plasma TBARS levels 
showed no significant differences (p<0.05) in all groups, 
including normal control, diabetic control and three isoflavone- 
supplemented groups (Table 5). When the TBARS content in 
the urine was calculated per 100 g body weight per day, it was 
found that the levels of all of the diabetic groups were 
significantly higher (p<0.05) than that of the normal control 
group. However, based on the amount of creatinine excreted, the 
urinary TBARS levels in all of the diabetic groups were 222 Isoflavone and diabetes
Table 5. Effects of soybean isoflavone extract supplementation on the levels
of TBA-reactive substances in plasma and urine of STZ-induced diabetic rats 
Groups (n)
2)
Plasma Urine Urine
(nmol/mL) (nmol/100 g 
BW/d)
(nmol/µmol 
creatinine)
Normal control (10) 8.37 ± 0.49
NS1)  48.39 ± 5.30
A 15.78 ± 0.37
A
Diabetic control (8) 8.25 ± 0.55
ns 107.97 ± 5.38
Bns  8.06 ± 0.88
Bns
Diabetic ISO-Ⅰ (9) 8.03 ± 1.07 118.53 ± 10.20
B  8.07 ± 0.39
B
Diabetic ISO-Ⅱ (13) 7.62 ± 0.48 119.94 ± 7.68
B  8.32 ± 0.71
B
Diabetic ISO-Ⅲ (12) 7.77 ± 0.42 114.95 ± 11.81
B  8.40 ± 0.58
B
ISO:  soybean  isoflavone  extract,  STZ:  streptozotocin
1) Mean ± S.E.
2) Number  of  animals 
Different  capital  superscripts  in  the  same  column  indicate  significant  difference 
(p<0.05)  among  5  groups  by  Duncan's  multiple  comparison  test. 
Different  small  superscripts  in  the  same  column  indicate  significant  difference 
(p<0.05)  among  4  diabetic  groups  by  Duncan's  multiple  comparison  test. 
NS Not  significantly  different  among  5  groups  (p<0.05)
ns N o t  s ig n if i c a n t l y  d i f f e r e n t  a m o n g  4  d i a b e t i c  g r o u p s  ( p <0.05)
Table 6. Effects of soybean isoflavone extract supplementation on the levels 
of TBA-reactive substances in liver, kidney and heart tissues of STZ-induced 
diabetic rats
Groups (n)
2) Liver Kidney Heart
(mmol/g tissue)
Normal control (10) 15.28 ± 0.51
A1) 50.48 ± 4.69
A 29.04 ± 1.64
NS
Diabetic control (8) 20.10 ± 0.78
Cc 65.72 ± 7.26
Ba 25.52 ± 1.03
ns
Diabetic ISO-Ⅰ (9) 17.77 ± 0.83
Bb 63.82 ± 3.08
Ba 25.56 ± 1.52
Diabetic ISO-Ⅱ (13) 14.38 ± 0.56
Aa 49.67 ± 4.27
Ab 26.72 ± 1.95
Diabetic ISO-Ⅲ (12) 14.45 ± 0.39
Aa 52.58 ± 4.16
Ab 29.00 ± 0.86
ISO:  soybean  isoflavone  extract,  TBA:  thiobarbituricacid,  STZ:  streptozotocin 
1) Mean ± S.E.
2) Number  of  animals 
Different  capital  superscripts  in  the  same  column  indicate  significant  difference 
(p<0.05)  among  5  groups  by  Duncan's  multiple  comparison  test. 
Different  small  superscripts  in  the  same  column  indicate  significant  difference 
(p<0.05)  among  4  diabetic  groups  by  Duncan's  multiple  comparison  test. 
NS Not  significantly  different  among  5  groups  (p<0.05)
ns N o t  s ig n if i c a n t l y  d i f f e r e n t  a m o n g  4  d i a b e t i c  g r o u p s  ( p <0.05)
Table 7. Effects of soybean isoflavone extract supplementation on hepatic 
antioxidant enzyme activities in STZ-induced diabetic rats 
Groups (n)
2)
CAT GPx SOD
(umol/min/
mg protein)
(nmol/min/
mg protein) (unit/mg protein)
Normal control (10) 2.46 ± 0.13
A1) 5.29 ± 0.32
NS 11.52 ± 0.14
A
Diabetic control (8) 1.73 ± 0.08
Bns 4.96 ± 0.17
ns 9.01 ± 0.38
Ca
Diabetic ISO-Ⅰ (9) 1.77 ± 0.13
B 5.18 ± 0.10 9.80 ± 0.08
Bb
Diabetic ISO-Ⅱ (13) 1.81 ± 0.07
B 5.24 ± 0.12 10.03 ± 0.12
Bb
Diabetic ISO-Ⅲ (12) 1.80 ± 0.05
B 4.97 ± 0.17 10.05 ± 0.21
Bb
ISO: soybean isoflavone extract, STZ: streptozotocin, GPx: glutathione peroxidase, 
SOD:  superoxide  dismutase
1) Mean ± S.E.
2) Number  of  animals 
Different  capital  superscripts  in  the  same  column  indicate  significant  difference 
(p<0.05)  among  5  groups  by  Duncan's  multiple  comparison  test.
Different  small  superscripts  in  the  same  column  indicate  significant  difference 
(p<0.05)  among  4  diabetic  groups  by  Duncan's  multiple  comparison  test.
NS Not  significantly  different  among  5  groups  (p<0.05)
ns N o t  s ig n if i c a n t l y  d i f f e r e n t  a m o n g  4  d i a b e t i c  g r o u p s  ( p <0.05)
Table 8. Effects of soybean isoflavone extract supplementation on plasma 
levels of vitamin A and E in STZ-induced diabetic rats 
Groups (n)
2) Vitamin A Vitamin E
(mmol/L)
Normal Control (10) 5.27 ± 0.10
A1) 331.00 ± 11.97
NS
Diabetic control (8) 4.50 ± 0.25
Ba 324.29 ± 13.93
ns
Diabetic ISO-Ⅰ (9) 4.69 ± 0.08
ABa 318.33 ± 11.35
Diabetic ISO-Ⅱ (13) 5.26 ± 0.20
Ab 311.28 ± 5.71
Diabetic ISO-Ⅲ (12) 5.06 ± 0.30
ABb 319.17 ± 9.29
ISO  :  soybean  isoflavone  extract,  STZ  :  streptozotocin 
1) Mean ± S.E.
2) Number  of  animals 
Different  capital  superscripts  in  the  same  column  indicate  significant  difference 
(p<0.05)  among  5  groups  by  Duncan's  multiple  comparison  test. 
Different  small  superscripts  in  the  same  column  indicate  significant  difference 
(p<0.05)  among  4  diabetic  groups  by  Duncan's  multiple  comparison  test. 
NS N o t  s i g n i f ic a n t ly  d if f e r e n t  a m o n g  5  g r o u p s  ( p <0.05) 
ns Not  significantly  different  among  4  diabetic  groups  (p<0.05) 
significantly lower (p<0.05) than that of the normal control 
group. 
The hepatic TBARS level in the diabetic control group was 
significantly higher (p<0.05) than that in the normal control 
group (Table 6). The hepatic levels of all the diabetic isoflavone- 
supplemented groups were significantly lower (p<0.05) than that 
of the diabetic control group. The levels of the ISO-II and ISO-III 
groups were significantly lower (p<0.05) than that of ISO-I group 
and were not significantly different in comparison to that of the 
normal control group. The TBARS level in renal tissue of the 
diabetic control group was significantly higher (p<0.05) than that 
of the normal control group. Among the diabetic groups, the 
levels of the ISO-II and ISO-III groups were significantly lower 
(p<0.05) than those of the diabetic control and ISO-I groups. 
There were no significant differences in regard to the TBARS 
levels in the heart tissue among all the groups, including the normal 
control, diabetic control and three isoflavone-supplemented 
groups. 
Effect on antioxidant enzyme activity in liver tissue
In comparison of the activities of antioxidant enzymes between 
the diabetic control and normal control groups, the catalase and 
SOD activities were significantly lower (p<0.05) in the diabetic 
control group, but there was no significant difference (p<0.05) 
in the activity of GPx (Table 7). Among the diabetic groups, 
there were no significant differences (p<0.05) in the activities 
of catalase and GPx. However, the SOD activities in all of the 
isoflavone-supplemented groups were significantly higher (p<0.05) 
than that in the diabetic control group.
Effect on plasma antioxidant vitamins 
The concentration of the plasma vitamin A in the diabetic 
control group was significantly lower (p<0.05) than that of the 
normal control group (Table 8). Vitamin A concentrations in the 
ISO-II and ISO-III groups were significantly higher (p<0.05) than 
those in the diabetic control and ISO-I groups. There were no 
significant differences (p<0.05) in the concentrations of vitamin 
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Discussion 
This study examined the effects of diets containing various 
levels of soy isoflavone extract on lipid profiles in the plasma 
and tissues, lipid peroxidation and antioxidant enzymes and 
vitamins in streptozotocin-induced diabetic rats. The supplementation 
of soybean isoflavone to diabetic rats significantly lowered the 
plasma cholesterol level, however, there was no effect on the 
plasma triglyceride level. Lee (2006) demonstrated that the 
concentrations of serum triglyceride and cholesterol were 
significantly reduced in diabetic groups fed a diet supplemented 
with genistein for 3 weeks. Ali et al. (2005) exhibited that soy 
isoflavones did not reduce triglyceride level in obese SHR/N-cp 
rats which are a genetic animal model of obesity and type 2 
diabetes. Hsu et al. (2003) reported that soy isoflavone 
supplementation had no significant effect on the reduction of 
triglyceride and cholesterol levels in fasting plasma, in which 
soy isoflavones at the three levels (240, 480, 1920 mg/100 g 
diet) were administrated to streptozotocin-induced diabetic rats 
for 24 days. From the previous studies conducted by other 
investigators, the effects of isoflavones on blood lipids in diabetic 
animals appeared inconsistent. 
The increases of total triglyceride and total cholesterol in 
plasma were frequently shown in diabetes mellitus states (Kaleem 
et al., 2006; Kesavulu et al., 2001; Lee, 2006). Insulin has a 
role in inhibiting the hormone sensitive lipase and activating 
lipoprotein lipase (LPL). Therefore, in diabetes state, the mobilization 
of free fatty acids from peripheral deposits is increased and serum 
total triglyceride levels are elevated (Al-Shamaony et al., 1994; 
Taskinen, 1987). However, in this study, the plasma triglyceride 
and cholesterol concentrations were significantly reduced in the 
diabetic control group in comparison to that in the normal control 
group. It may be inferred that the decreased levels of these lipids 
in the present study might have been caused by the markedly 
reduced body weight in the diabetic rats, which was reported 
in the previous paper by Shim et al. (2007). At the end of 7 
weeks of experiment period, the mean final body weight of the 
normal control and the diabetic control groups was 522.50 g and 
277.36 g, respectively. We had previously obtained similar results 
from several studies using diabetic animals (Lee et al., 1996; 
Park & Lee, 2003). 
It has been observed in this study that the supplementation 
of soybean isoflavone at the levels of 3.0 mg (ISO-II) and 30 
mg (ISO-III) per kilogram of body weight per day in diabetic 
rats resulted in the increases of plasma HDL-cholesterol, the ratio 
of HDL-cholesterol/total cholesterol in plasma and remarkable 
improvement of atherogenic index. Anthony et al. (1996) reported 
that soy protein including isoflavone significantly increased the 
concentration of HDL-cholesterol and the ratio of HDL-cholesterol/ 
total cholesterol and also significantly reduced the total plasma 
cholesterol concentrations in rhesus monkeys. Lee (2006) 
demonstrated that a 60 mg/100 g diet of genistein increased the 
serum HDL-cholesterol level in diabetic rats. Jayagopal et al. 
(2002) presented that a diet supplemented with phytoestrogens 
(soy protein 30 g/d, isoflavones 132 mg/d) for 12 week 
significantly lowered total cholesterol, LDL cholesterol and 
cholesterol/HDL cholesterol ratio in postmenopausal women with 
type 2 diabetes mellitus. The results of these studies support the 
conclusion that soybean isoflavones may be effective in improving 
the plasma lipid profiles in diabetes mellitus.
It is known that the quantity of triglycerides in the liver is 
significantly increased in uncontrolled diabetes mellitus, which 
results from raised plasma free fatty acids levels. Since the 
antilipogenic effect of isoflavone has been reported (Duncan et 
al., 1999; Naaz et al., 2003), we hypothesized that hepatic lipid 
content in diabetic rats might be reduced by isoflavone 
supplementation. However, in this study, the concentrations of 
hepatic triglyceride and cholesterol were not significantly 
reduced in the isoflavone-supplemented groups in comparison to 
that in the diabetic control group. Lee (2006) reported a significant 
reduction of hepatic fat contents in diabetic rats fed a diet 
supplemented with genistein at the intake level of 60 mg/100 
g diet for 3 weeks. Compared to the above mentioned study, 
we supplemented less amounts of isoflavones (0.42-25.40 mg/100 
g diet) for longer period (7 weeks). It could be assessed that 
the reduction of hepatic lipid levels by isoflavone might be 
impacted by the amount of isoflavone supplement and the 
duration of diabetic state. On the other hand, the significant 
reduction of hepatic triglyceride in the diabetic control group 
in comparison to that in the normal control group might be due 
to the severe loss of body weight in diabetic state. 
It has been reported that lipid peroxides levels have been 
elevated in humans with diabetes (Griesmacher et al., 1995; Turk 
et al., 2002) as well as diabetic rats (Lee, 2006; Morel & Chisolm, 
1989). In diabetic state, hyperglycemia may induce a formation 
of reducing sugars through glycolysis and polyol pathway. These 
reducing sugars can easily react with lipids and proteins 
(nonenzymatic glycation reaction), increasing the production of 
reactive oxygen species (Kaneto et al., 1996; Palmeira et al., 
2001). In the study of Griesmacher et al. (1995), the serum 
TBARS levels were significantly increased in all patients 
suffering from diabetes mellitus, suggesting that the increased 
formation of free radicals was responsible for the enhanced lipid 
peroxidation. Morel and Chisolm (1989) reported that lipid 
oxidation had been increased in a lipoprotein fraction containing 
VLDL and LDL of diabetic rats. They also demonstrated the 
relationship between the in vivo oxidation of lipoproteins in 
diabetes and the potential for tissue damage as monitored by 
in vitro cytotoxicity. Whereas, in the study of Seven et al. (2004), 
plasma lipid peroxide levels between the normal control and the 
diabetic control groups were not significantly different, which were 
consistent with the results of this study. The supplementation 
of soybean isoflavone had no significant effect on the reduction 
of plasma TBARS in diabetic rats in our study. However, urinary 
excretion of TBARS per 100 g body weight per day was 
significantly increased in all diabetic groups over that in the 224 Isoflavone and diabetes
normal control group. It seemed to be due to the kidney's 
compensatory mechanism for the elimination of the increased 
lipid peroxides in vivo. The increased urinary TBARS has been 
considered as a biomarker for the increased lipid peroxidation 
in vivo under diabetic conditions. Gallaher et al. (1993) reported 
that the urinary excretion of TBARS in diabetic rats was increased 
5-fold compared to that in normal rats. When the amounts of 
urinary TBARS were calculated based on the amount of 
creatinine excreted, the TBARS levels of the diabetic groups were 
significantly lower than that of the normal control group. This 
result might be explained from the increased excretion of 
creatinine induced by the accelerated degradation of lean body 
mass in the diabetic state, compared to the normal condition. 
The TBARS levels of the liver and kidney tissues in the 
diabetic control group were significantly higher than that in the 
normal control group, which were consistent with the results of 
previous studies (Kaleem et al., 2006; Lee, 2006; Seven et al., 
2004). The supplementations of both 3.0 mg and 30.0 mg 
soybean isoflavone extract per kilogram of body weight per day 
significantly lowered the levels of TBARS in the liver and kidney 
to almost that of the normal control group. Lee (2006) reported 
that the administration of genistein significantly decreased the 
level of hepatic TBARS, which was significantly elevated in 
streptozotocin-induced diabetic rats. These results indicate that 
isoflavones may have a beneficial effect on the reduction of lipid 
peroxidation in the liver and kidney. 
The effects of soybean isoflavone extract on antioxidant system 
in diabetic rats were investigated. Antioxidant enzymes and 
antioxidant vitamins play major roles in eliminating lipid 
peroxides produced in in vivo oxidative reactions. The activities 
of hepatic catalase and superoxide dismutase (SOD) in the 
diabetic control group were significantly reduced in comparison 
to those in the normal control group, which were consistent with 
the results of previous studies (Kaleem et al., 2006; Lee, 2006). 
Kaleem et al. (2006) stated that the decreased activities of SOD 
and catalase in both liver and kidney during diabetic state may 
be due to the production of reactive oxygen free radicals that 
can themselves reduce the activity of these enzymes. However, 
all diabetic groups fed the soybean isoflavone-supplemented diets 
(0.4-25 mg/100 g diet) significantly increased the activities of 
SOD. In the study of Hsu et al. (2003), a 240-1920 mg/100 g 
diet of soy isoflavone had no effect on the increases of SOD 
and GPx activities in diabetic rats. Lee (2006) reported that 60 
mg/100 g diet of genistein significantly increased the activities 
of catalase, SOD and GPx in diabetic rats. Therefore, the 
relationship between the supplementation level of isoflavones and 
the activities of antioxidant enzymes in diabetic animals need 
to be further elucidated. 
The SOD converts superoxide anions (O2-) into hydrogen 
peroxide (H2O2), which, in turn, is degraded to H2O or GSSG 
by catalase or GPx in the biological antioxidant defense system. 
Based on the results of this study, the hydrogen peroxides 
produced by hepatic SOD in diabetic groups supplemented with 
soybean isoflavone seem to be insufficiently eliminated by 
catalase and GPx in comparison to the normal control group. 
Therefore, it is difficult to fully ascertain that the administration 
of soybean isoflavone to diabetic rats may strengthen the antioxidant 
enzyme systems to scavenge lipid peroxides. The significant 
reduction of TBARS in the liver and kidney tissues, observed 
in this study, appeared not to be related to antioxidant enzyme 
system, but to the antioxidative property of isoflavone itself. 
Therefore, we suggest that soybean isoflavone might have a 
major role in the suppression of lipid peroxidation as a powerful 
antioxidant in the liver and kidney of diabetic rats. The 
antioxidative effect of isoflavones had been also reported in 
previous studies (Pratt et al., 1981; Wei et al., 1993; Wei et 
al., 1996).
The plasma vitamin A level in the diabetic control was 
significantly decreased in comparison to that in the normal 
control group. This result was in agreement with that of the 
previous study (Tuitoek et al., 1996) in which plasma retinol- 
binding proteins and retinol were measured in streptozotocin- 
induced diabetic rats. They demonstrated that decreased plasma 
retinol concentration in diabetic rats may be induced, at least 
in part, by impaired metabolic transport from the liver. It is also 
hypothesized that the decreased plasma vitamin A level in 
diabetic state may be induced by the increased utilization of 
vitamin A in eliminating or suppressing excess lipid peroxides. 
The supplementation of soy isoflavone in diabetic rats shows 
a remarkable effect on the elevation of vitamin A concentration 
in plasma, especially at the dosage level of 3.0 mg per kilogram 
of body weight. The level of plasma vitamin A was the highest 
among diabetic groups and similar to that of normal control 
group. We could not explain the mechanisms which induced the 
increases of plasma vitamin A in isoflavone-supplemented diabetic 
rats, considered to be beyond the scope of this study. To our 
knowledge, the effects of soybean isoflavones on the transport 
of vitamin A from the liver to plasma in diabetic animals have 
not yet been reported. The results of plasma vitamin E levels 
of diabetic rats compared to normal rats were inconsistent with 
the results of previous studies (Alper et al., 2006; Ravi et al., 
2004). In this study, there were no significant differences between 
the normal control and the diabetic control groups in plasma 
vitamin E level. It might be partially explained due to the 
antioxidant property of vitamin C. When vitamin E interacts with 
lipid radicals, the vitamin E itself forms α-tocopheroxyl radicals, 
which can be regenerated to vitamin E by vitamin C in biological 
system (Alper et al., 2006; Packer 1993). Although the experimental 
diets used in this study did not contain vitamin C (Table 1), 
it is possible because rats are able to biosynthesize vitamin C 
by itself. 
In conclusion, the present study has demonstrated that the 
dosage levels of both 3.0 mg and 30.0 mg soybean isoflavone 
extract per kilogram of body weight may have favorable effects 
on the lipid profiles and antioxidant activities, in part, by 
decreasing the plasma total cholesterol level as well as TBARS Jee-youn Shim et al. 225
levels in the liver and kidney, simultaneously, and by increasing 
the levels of plasma HDL-cholesterol and vitamin A as well as 
the activity of hepatic superoxide dismutase. As no significant 
differences were found between the ISO-II and ISO-III groups, 
we suggest that 3.0 mg of soy isoflavone per kilogram of body 
weight might be a suitable daily dosage to alleviate lipid 
disturbances in diabetic rats. 
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